This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letter  • Similar articles in this journal  Topic Collections  • Neuro-ophthalmology  • Statistics and Research Methods  • Alert me on articles by topic  Social Bookmarking   What's this?

Marc Gotkine, MBBS

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The long-term results of the Optic Neuritis Treatment Trial (ONTT)¹ will certainly allow clinicians to provide clearer information to people presenting with an initial episode of optic neuritis and may also facilitate better design of treatment trials.

Although it is unlikely that many patients in the sample had their serum tested for neuromyelitis optica (NMO) IgG, it would be interesting to know how many went on to develop a longitudinally extensive spinal cord lesion as it is possible that some of them now fulfill the revised diagnostic criteria for NMO as proposed by Wingerchuk et al.² Furthermore, the data may suggest ways of predicting the future development of NMO, especially as characteristic brain magnetic resonance imaging features have been described.^3-4

Given the differences in prognosis and response to treatment of NMO when compared with multiple sclerosis,² it may be important to take account of the recent advances . . . [Full Text of this Article]

AUTHOR INFORMATION



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Multiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-up
The Optic Neuritis Study Group
Arch Neurol. 2008;65(6):727-732.
ABSTRACT | FULL TEXT  

RELATED LETTER

Neuromyelitis Optica and the Optic Neuritis Treatment Trial—Reply
Craig H. Smith
Arch Neurol. 2008;65(11):1546.
EXTRACT | FULL TEXT